Showing results (161-170 of 399) with videos related to

Sort By:
Pageof 40
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Leukemia Research|September 15, 2022
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclaxJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 2, 2024
Transmural Flow Upregulates PD-L1 Expression in Microvascular NetworksZhengpeng Wan, Shun Zhang, Amy X Zhong, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
British Journal of Cancer|May 17, 2018
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancersJorge Cortes, Kenji Tamura, Daniel J DeAngelo, et al.
The Journal of Clinical Investigation|June 29, 2023
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancerFrancesca Nardi, Naiara Perurena, Amy E Schade, et al.
Cancer Research Communications|November 24, 2025
Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1-Mutant Lung CancerToshiyuki Tenma, Ryohei Yoshida, Hiraku Yanada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2021
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, et al.
Pageof 40